Asian Penny Stocks To Watch In October 2025

Amid renewed U.S.-China trade tensions and concerns over a prolonged U.S. government shutdown, Asian markets have shown resilience with mixed performances across major indices. Despite the global uncertainties, investors continue to explore opportunities within various sectors, including the often-overlooked realm of penny stocks. While the term 'penny stocks' may seem outdated, these smaller or newer companies can offer significant value when backed by strong financials and potential for growth.

Top 10 Penny Stocks In Asia

Click here to see the full list of 960 stocks from our Asian Penny Stocks screener.

Let's dive into some prime choices out of the screener.

International Cement Group (SGX:KUO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: International Cement Group Ltd. operates in the production, sale, and distribution of cement and gypsum plasterboards across several countries including Singapore, Malaysia, Afghanistan, Tajikistan, and Kazakhstan with a market cap of SGD286.74 million.

Operations: The company's revenue is primarily derived from its cement segment, which generated SGD305.11 million, complemented by smaller contributions from the aluminium segment at SGD5.25 million.

Market Cap: SGD286.74M

International Cement Group Ltd. recently reported significant improvements in earnings, with net income rising to SGD14.88 million for the half year ended June 30, 2025, compared to SGD0.933 million a year ago. The company has demonstrated robust revenue growth in its cement segment while maintaining a low net debt to equity ratio of 11.6%, which is considered satisfactory. Despite experiencing high share price volatility over the past three months, International Cement Group's interest payments are well covered by EBIT at 20.7 times coverage, and its profit margins have improved from last year's figures, indicating potential financial stability amidst market fluctuations.

• Click here to discover the nuances of International Cement Group with our detailed analytical financial health report.
• Evaluate International Cement Group's historical performance by accessing our past performance report.

Tengda Construction Group (SHSE:600512)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Tengda Construction Group Co., Ltd. operates in the infrastructure construction sector in China and has a market capitalization of CN¥4.02 billion.

Operations: The company generates revenue of CN¥3.63 billion from its operations within China.

Market Cap: CN¥4.02B

Tengda Construction Group has faced challenges, with earnings declining by 49.1% annually over the past five years and a recent dip in revenue to CN¥1.61 billion for H1 2025 compared to CN¥1.70 billion a year earlier. Despite these setbacks, the company remains debt-free and possesses substantial short-term assets of CN¥7.4 billion, comfortably covering both short and long-term liabilities. However, its profit margins have narrowed from 2.4% to 0.7%, and its return on equity is low at 0.4%. The board's average tenure of 2.9 years suggests relatively new leadership navigating these financial hurdles.

• Click to explore a detailed breakdown of our findings in Tengda Construction Group's financial health report.
• Review our historical performance report to gain insights into Tengda Construction Group's track record.

HARBIN GLORIA PHARMACEUTICALS (SZSE:002437)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Harbin Gloria Pharmaceuticals Co., Ltd focuses on the research, development, production, and sale of pharmaceutical products primarily in China with a market capitalization of CN¥7.10 billion.

Operations: The company's revenue is derived from its Chemical Medicine segment, generating CN¥2.12 billion, and its Traditional Chinese Medicine segment, contributing CN¥190.33 million.

Market Cap: CN¥7.1B

Harbin Gloria Pharmaceuticals has demonstrated financial stability with more cash than debt and strong short-term assets of CN¥988.8 million exceeding liabilities. Its earnings have grown by 11.6% over the past year, surpassing industry averages, although this growth is below its five-year average of 71.5%. The company's net profit margin improved to 10.4%, aided by a significant one-off gain of CN¥93.1 million in the last year, which may not reflect ongoing operations' performance. Despite trading at a discount to estimated fair value, its relatively inexperienced board and low return on equity at 12% are potential concerns for investors.

• Navigate through the intricacies of HARBIN GLORIA PHARMACEUTICALS with our comprehensive balance sheet health report here.
• Examine HARBIN GLORIA PHARMACEUTICALS' earnings growth report to understand how analysts expect it to perform.

Turning Ideas Into Actions

• Dive into all 960 of the Asian Penny Stocks we have identified here.
• Contemplating Other Strategies? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com